Metformin for Gestational Diabetes Mellitus: Progeny, Perspective, and a Personalized Approach
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Given the rapidly growing population of women diagnosed with gestational diabetes mellitus (GDM), approximating 1 in 7 pregnancies globally (1), in conjunction with the rising cost of insulins and lack of affordability (2), the popularity of using an oral agent such as metformin is expanding enormously. In fact, a number of organizations have supported its use as an alternative to insulin (3–6). However, recent long-term studies on offspring have provided conflicting results, with two of three studies recently published on the 4- to 9-year-old children of mothers with GDM or polycystic ovarian syndrome (PCOS) suggesting some long-term metabolic programming effects on the offspring (7–9). This has given some clinical investigators and organizations (10,11) pause in embracing metformin as equivalent to insulin (12–17). In the short term, there is an abundance of evidence that metformin has a safe track record and may have some benefits compared with insulin or glyburide when used for the treatment of GDM (18). Metformin is not teratogenic, with reassuring data for use in the first trimester (19–21), and in several meta-analyses, women with GDM randomized to metformin (often used with insulin) had less gestational weight gain, less gestational hypertension, and fewer infants who were large-for-gestational age (LGA) or with macrosomia (birth weight >4,000 g), and their infants had less neonatal hypoglycemia, than those randomized to insulin or glibenclamide (glyburide) therapy (22–24). However, metformin has a high failure rate, and 46% of women randomized to metformin needed to add insulin in the Metformin in Gestational Diabetes (MiG) randomized controlled trial (RCT) (25). In comparison, in a large multisite RCT in which insulin was compared with glyburide for GDM, the failure rate of glyburide was 18% (26). Important in interpreting RCT data is that glyburide …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“None of the currently available human insulin preparations have been demonstrated to cross the placenta (93-98).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [95]
In the citing paper
“However, due to the potential for growth restriction or acidosis in the setting of placental insufficiency, metformin should not be used in pregnant people with hypertension or preeclampsia or those at risk for intrauterine growth restriction (90,95,96).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [95]
Citations
Cites
ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002501 · Cited by 1,820
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 12×
“In a recent publication, investigators analyzed 182 offspring at 4 years of age (55% of the total cohort) from two RCTs of women with PCOS (8).”
BackgroundInfluentialHod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., Roura, L. C., McIntyre, H. D., Morris, J. L., & Divakar, H. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30033-3 · Cited by 767
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
Balsells, M., Garcia-Patterson, A., Sola, I., Roque, M., Gich, I., & Corcoy, R. (2015) · BMJ · doi:10.1136/bmj.h102 · Cited by 498
Metformin versus placebo in obese pregnant women without diabetes mellitus
Syngelaki, A., Nicolaides, K. H., Balani, J., Hyer, S., Akolekar, R., Kotecha, R., Pastides, A., & Shehata, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509819 · Cited by 394
Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)
Rowan, J. A., Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Hague, W. M. (2011) · Diabetes Care · doi:10.2337/dc11-0660 · Cited by 379 · cited 1×
“No measure of visceral fat was given (45) and no differences were found in neurodevelopmental outcomes.”
BackgroundThompson, D., Berger, H., Feig, D., Gagnon, R., Kader, T., Keely, E., Kozak, S., Ryan, E., Sermer, M., & Vinokuroff, C. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.044 · Cited by 377
Self-citationFeig, D. S., Berger, H., Donovan, L., Godbout, A., Kader, T., Keely, E., & Sanghera, R. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.038 · Cited by 344
Self-citationVanky, E., Stridsklev, S., Heimstad, R., Romundstad, P., Skogøy, K., Kleggetveit, O., Hjelle, S., von Brandis, P., Eikeland, T., Flo, K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0853 · Cited by 315
Research works printed but not linked: 1
- American Diabetes Association, 2018, 13. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes—2018, Diabetes Care, 41
Cited by
McIntyre, H. D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E. R., & Damm, P. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0098-8 · Cited by 1,850
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s014 · Cited by 381
15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s014 · Cited by 268
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s015 · Cited by 252
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s015 · Cited by 232
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Brown, F. M., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s015 · Cited by 176
Tsakiridis, I., Giouleka, S., Mamopoulos, A., Kourtis, A., Athanasiadis, A., Filopoulou, D., & Dagklis, T. (2021) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000899 · Cited by 94
“Additionally, according to ADA, the use of metformin is contraindicated in the presence of hypertension, preeclampsia, and high-risk of fetal growth restriction because of its potential association with those pregnancy complications.(67) Regarding glyburide, the NICE states that it should be considered for cases that…”
Wyckoff, J., Lapolla, A., Asias-Dinh, B. D., Barbour, L. A., Brown, F. M., Catalano, P. M., Corcoy, R., Renzo, G. C. D., Drobycki, N., Kautzky‐Willer, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf288 · Cited by 60
“Unlike insulin, metformin has been found to exhibit marked maternal-to-fetal transfer, achieving fetal levels at least as high as maternal levels due to high expression of OCT3 cation transporters in the placenta in the second and third trimesters (140).”
Self-citationGestational Diabetes: An Update 60 Years After O’Sullivan and Mahan
McIntyre, H. D., Kampmann, U., Dalsgaard Clausen, T., Laurie, J., & Ma, R. C. W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae709 · Cited by 32
Unravelling Polycystic Ovary Syndrome and Its Comorbidities
Kim, K.-W. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21043 · Cited by 44
“especially if relative nutrient restriction in utero is followed by later exposure of the offspring to an obesogenic environment.(62) Therefore, when used to treat PCOS and induce ovulation, metformin should be discontinued by the end of the first trimester according to the 2021 Standards of Medical Care in Diabetes f…”
BackgroundVenkatesh, K. K., Chiang, C., Castillo, W. C., Battarbee, A., Donneyong, M. M., Harper, L. M., Costantine, M. M., Saade, G. A., Werner, E., Boggess, K., et al. (2021) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16960 · Cited by 29
Wyckoff, J., Lapolla, A., Asias-Dinh, B. D., Barbour, L. A., Brown, F. M., Catalano, P. M., Corcoy, R., Renzo, G. C. D., Drobycki, N., Kautzky‐Willer, A., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf116 · Cited by 31
“Unlike insulin, metformin has been found to exhibit marked maternal-to-fetal transfer, achieving fetal levels at least as high as maternal levels due to high expression of OCT3 cation transporters in the placenta in the second and third trimesters 140 .”
Self-citationMetformin Disrupts Signaling and Metabolism in Fetal Hepatocytes
Swenson, K. S., Wang, D., Jones, A. K., Nash, M. J., O’Rourke, R., Takahashi, D. L., Kievit, P., Hennebold, J. D., Aagaard, K. M., Friedman, J. E., et al. (2023) · Diabetes · doi:10.2337/db23-0089 · Cited by 23
Lin, S., Chang, S., Kuo, C., Lin, W., Chiou, M., & Huang, Y. (2020) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-020-03207-0 · Cited by 18
Management of Women with Polycystic Ovary Syndrome During Pregnancy
Valent, A. M., & Barbour, L. A. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.10.005 · Cited by 17
Self-citationA Glimpse at the Size of the Fetal Liver—Is It Connected with the Evolution of Gestational Diabetes?
Cozma, M.-A., Găman, M., Dobrică, E.-C., Boroghină, S. C., Iancu, M. A., Creţoiu, S. M., & SIMIONESCU, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157866 · Cited by 17
“A personalized approach to pharmacological treatment is recommended [44].”
BackgroundMetformin Perturbs Pancreatic Differentiation From Human Embryonic Stem Cells
Nguyen, L. T. V., Lim, L. Y., Ding, S. S. L., Amirruddin, N. S., Hoon, S. S., Chan, S., & Teo, A. K. K. (2021) · Diabetes · doi:10.2337/db20-0722 · Cited by 18
Screening and management of major endocrinopathies during pregnancy: an update
Paschou, S. Α., Bletsa, E., Papazisi, M., Mili, N., Kanouta, F., Kassi, G., Ψαλτοπούλου, Θ., Goulis, D. G., & Lambrinoudaki, I. V. (2022) · Endocrine · doi:10.1007/s12020-022-03237-y · Cited by 14
Safiah, M., Hyassat, D., Khader, Y. S., Farahid, O., Batieha, A. M., El-Khateeb, M. S., & Ajlouni, K. M. (2021) · Journal of Diabetes Research · doi:10.1155/2021/8275303 · Cited by 17
Gestational Diabetes Mellitus: Diagnosis and Glycemic Control
Oh, T. J., & Jang, H. C. (2020) · Journal of Korean Diabetes · doi:10.4093/jkd.2020.21.2.69 · Cited by 6
Position statement of Italian Society of Obesity (SIO): Gestational Obesity
Barrea, L., Camastra, S., Garelli, S., Guglielmi, V., Manco, M., Velluzzi, F., Barazzoni, R., Verde, L., & Muscogiuri, G. (2024) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-024-01688-y · Cited by 5
“…with an acceleration of postnatal growth and a higher BMI in childhood, so guidelines do not recommend metformin as the first-line treatment for GDM [196] and suggest caution, especially in pregnant women with hypertensive disorders or at risk for intrauterine growth restriction [197, 198].”
BackgroundKelly, L., Kattini, R., & Hummelen, R. (2023) · Canadian Journal of Rural Medicine · doi:10.4103/cjrm.cjrm_40_22 · Cited by 6
Review of Prediabetes and Hypertensive Disorders of Pregnancy
Carris, N. W., Nwabuobi, C. K., He, W., Bullers, K., Wilson, R. E., Louis, J. M., & Magness, R. R. (2019) · American Journal of Perinatology · doi:10.1055/s-0039-1698831 · Cited by 4
Metformin therapy in pregnancy [Zastosowanie metforminy w ciąży]
Krupej, J., Cichocka, E., Kędzierski, L., Okopień, B., & Gumprecht, J. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2020.0016 · Cited by 2
Farladansky‐Gershnabel, S., Sachs, D. L., Qadir, N. A. E., Ram, R. B., Biron‐Shental, T., Kovo, M., & Ravid, D. (2025) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-025-08029-z · Cited by 2
“However, it is important to note that empirical evidence from human pregnancy outcomes has hitherto not demonstrated these theoretical adverse effects [27].”
D’Souza, A., Abdullahi, H., Badri, F., & Ibrahim, I. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07869-6 · Cited by 5
“As the effect of metformin on the mammalian target of the rapamycin (mTOR) signaling pathway could cause nutrient restriction to the fetus and placenta [39, 40], there is potential for acidosis or fetal growth restriction, especially in the setting of placental insufficiency [41].”
Rommy, Karinaningrum, A. D., Luthfiananda, B., Aniq, L., Evelina, L. S., & Fauzi, R. (2022) · Indonesian Journal of Pharmacology and Therapy · doi:10.22146/ijpther.3244 · Cited by 1
Fan, X., Wang, C., Chen, L., Zhao, X., Wu, Y., & Zeng, G. (2024) · American Journal of Translational Research · doi:10.62347/nigm4906 · Cited by 2
Hipoglucemiantes orales en el control metabólico de la diabetes gestacional.
Lazo-Feijoo, L. A., & Campoverde, L. H. M. (2023) · MQRInvestigar · doi:10.56048/mqr20225.7.3.2023.2454-2482
Barbour, L. A., & Feig, D. S. (2019) · Diabetes Care · doi:10.2337/dci19-0025
“Rowan’s thoughtful comments (1) on our article (2), as her comments make a number of important points.”
BackgroundSelf-citationRowan, J. (2019) · Diabetes Care · doi:10.2337/dc19-0654
“Considering adverse versus beneficial long-term effects of metformin exposure in utero, Barbour and Feig outline their concerns based on themechanisms of the action of metformin and its potential to attenuate nutrient flux and fetal growth.”
BackgroundInfluentialProtocolo diagnóstico y terapéutico de la diabetes en el embarazo
Sanz‐Cánovas, J., Ricci, M., Buonaluto, V., & Huelgas, R. G. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.026
Oral anti-diabetics for gestational diabetes mellitus – where do we stand?
Cudalbă, D., Gică, C., Botezatu, R., Gică, N., Ciobanu, A. M., Peltecu, G. C., & Panaitescu, A. M. (2020) · Romanian Medical Journal · doi:10.37897/rmj.2020.3.2
Koufakis, T., Garas, A., Zebekakis, P. E., & Kotsa, K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942842
“GDM – similar to any other type of diabetes – requires a holistic and tailored approach to its management, which considers the unique biological, psychosocial and socioeconomical features of each woman [15].”
BackgroundInfluentialThe Gestational Diabetes Mellitus Approach in Clinical Practice – A Narrative Review
Deteșan, O., Custură, L. M., Schmiedt, R. A., Bacso, B. I., Bell, A. C., Streza, M. A., & Tilinca, M. C. (2021) · Acta Marisiensis. Seria Medica · doi:10.2478/amma-2021-0037
Chatzakis, C., Sotiriadis, A., Gerede, A., Dinas, K. D., & Nicolaides, K. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-89243-2_16
Metformin in pregnancy: everything you always wanted to know but were afraid to ask
Biamonte, E. (2023) · The Journal of AMD · doi:10.36171/jamd23.26.3.4
Rozance, P. J., Brown, L. D., & Wesolowski, S. R. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01547-2
“Metformin is a leading medication for the treatment of Type-2 diabetes (T2D) in adults and is recommended as an alternative to insulin in women with T2D or gestational diabetes [1].”
BackgroundGestational diabetes mellitus: ensuring healthy futures
Morgan, H. D., Hamza, M., Morrison, A., Campbell, C., Cassar, C. B., Thayyil, S., & Meek, C. L. (2024) · British Journal of Midwifery · doi:10.12968/bjom.2024.0054
Lin, S.-F., Chang, S., Kuo, C.-F., Lin, W.-T., Chiou, M.-J., & Huang, Y.-T. (2020) · Figshare · doi:10.6084/m9.figshare.12922819
Sun, L., Du, P., & Xi, Z. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-08649-6 · Cited by 3
“Thus, the long-term safety of metformin for the fetus remains uncertain, and further large-scale, long-term cohort studies (≥ 10 years) are needed to fully evaluate its impact on the offspring’s growth, development, and metabolic health [39, 40].”
Metadata
- Authors
- Barbour, L. A., & Feig, D. S.
- Affiliations
- University of Colorado Anschutz (US)
- University of Toronto (CA)
- Corresponding author
- Barbour, Linda A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-02-12
- Volume
- 42
- Issue
- 3
- Pages
- 396-399
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2915607850
- Cited by
- 44
- References
- 52
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 4 · 2021: 11 · 2020: 7 · 2019: 5
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- metformin, gestational diabetes mellitus, insulin therapy, glibenclamide, offspring metabolic programming, polycystic ovary syndrome, teratogenicity, gestational weight gain, macrosomia, neonatal hypoglycemia, personalized treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.